Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001703558 | SCV000516669 | likely benign | not provided | 2020-09-02 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 30739908) |
Color Diagnostics, |
RCV001191117 | SCV001358813 | likely benign | Familial thoracic aortic aneurysm and aortic dissection | 2018-11-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002061627 | SCV002454908 | likely benign | Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection | 2023-12-12 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001703558 | SCV002506070 | likely benign | not provided | 2022-02-01 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV002265759 | SCV002547851 | uncertain significance | not specified | 2022-05-17 | criteria provided, single submitter | clinical testing | Variant summary: FBN1 c.5225-13T>G alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Two predict the variant weakens a 3' acceptor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 3.6e-05 in 249896 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.5225-13T>G has been reported in the literature in an individual affected with thoracic aortic aneurysms and dissections without strong evidence for causality (Arnaud_2019). This report does not provide unequivocal conclusions about association of the variant with Marfan Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as VUS - possibly benign. |
All of Us Research Program, |
RCV003996026 | SCV004824071 | likely benign | Marfan syndrome | 2023-12-18 | criteria provided, single submitter | clinical testing |